Combination of B-type natriuretic peptide and minute ventilation/carbon dioxide production slope improves risk stratification in patients with diastolic heart failure

被引:23
|
作者
Yan, Jing [1 ]
Gong, Shi-Jin [1 ]
Li, Li [1 ]
Yu, Hai-Yan [1 ]
Dai, Hai-Wen [1 ]
Chen, Jin [1 ]
Tan, Cheng-Wu [1 ]
Xv, Qiang-Hong [1 ]
Cai, Guo-Long [1 ]
机构
[1] Zhejiang Hosp, Intens Care Unit, Zhejiang Prov Key Lab Geriatr, Hangzhou 310013, Zhejiang, Peoples R China
关键词
Diastolic heart failure; B-type natriuretic peptide; Exercise testing; Prognosis; EXERCISE OXYGEN-CONSUMPTION; VENTILATORY EFFICIENCY; DOPPLER-ECHOCARDIOGRAPHY; EJECTION FRACTION; PROGNOSTIC VALUE; DYSFUNCTION; PREVALENCE; PREDICTOR; POWER;
D O I
10.1016/j.ijcard.2011.07.017
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Recent studies demonstrated that the minute ventilation/carbon dioxide production (VE/VCO2) slope more powerfully predicted mortality, hospitalization, or both than peak oxygen consumption (VO2) in systolic heart failure. However, the prognostic values of these two parameters in diastolic heart failure remained unclear. Methods: The patients with diastolic heart failure were recruited from April 2006 to May 2007, and underwent cardiopulmonary exercise testing. Plasma BNP concentration was measured using Triage BNP immunoassay method. Results: Of the 224 patients enrolled, mean values for age and New York Heart Association (NYHA) class were 68.8 +/- 9.0 years and 2.38 +/- 0.53, respectively. During the mean follow-up of 30 months, 57 patients died (36 from cardiovascular death). Univariate Cox regression analysis showed that age, NYHA class, atrial fibrillation, diabetes mellitus, left ventricular diastolic dysfunction, peak VO2, VE/VCO2 slope, and plasma BNP were significantly associated with mortality. Multivariate analysis revealed that plasma BNP, VE/VCO2 slope, and age remained independent predictors for cardiovascular and all-cause mortalities, with the strongest prognostic power of plasma BNP (chi(2) >= 31.4, P < 0.001). In addition to plasma BNP and clinical predictors, the VE/VCO2 slope could provide independent and incremental prognostic value of cardiovascular (chi(2) = 60.6 vs 51.7; P=0.009) and all-cause mortalities (chi(2) = 62.8 vs 54.2; P = 0.015) with increased chi(2) value of Cox regression model. Conclusion: In diastolic heart failure, plasma BNP is the strongest predictor of mortality, and VE/VCO2 slope provides independent and additive prognostic information, which suggests that combination of plasma BNP and VE/VCO2 slope can improve risk stratification. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:193 / 198
页数:6
相关论文
共 50 条
  • [1] Combination of B-Type Natriuretic Peptide and Minute Ventilation Carbon Dioxide Production Slope Improves Risk Stratification in Patients with Diastolic Heart Failure
    Yan, Jing
    Li, Li
    Gong, Shi-jin
    Dai, Hai-wen
    Chen, Jin
    Yu, Yi-hua
    Xv, Qiang-hong
    Cai, Guo-long
    CIRCULATION, 2011, 124 (21)
  • [2] Combination of B-type Natriuretic Peptide and MIBG wash out rate improves risk stratification in patients with advanced heart failure
    Despas, F.
    Cagnac, R.
    Guerrierro, E.
    Senard, J. M.
    Galinier, M.
    Pathak, A.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2007, 21 : 26 - 26
  • [3] Combination of B-type natriuretic peptide and peak oxygen consumption improves risk stratification in outpatients with chronic heart failure
    Isnard, R
    Pousset, F
    Chafirovskaïa, O
    Carayon, A
    Hulot, JS
    Thomas, D
    Komajda, M
    AMERICAN HEART JOURNAL, 2003, 146 (04) : 729 - +
  • [4] Risk stratification using a combination of cystatin C and B-type natriuretic peptide after additional treatment in patients with chronic heart failure
    Kuno, A.
    Ishii, J.
    Kitagawa, F.
    Ishikawa, T.
    Fujita, T.
    Nakano, T.
    Naruse, H.
    Matsui, S.
    Tanaka, I.
    Ozaki, Y.
    Hishida, H.
    Oshima, H.
    CLINICAL CHEMISTRY, 2007, 53 (06) : A10 - A10
  • [5] Risk stratification using a combination of cystatin-C and B-type natriuretic peptide in patients hospitalized for worsening chronic heart failure
    Ishii, J
    Ozaki, Y
    Nakano, T
    Nakamura, Y
    Naruse, H
    Mori, Y
    Matsui, S
    Kondo, T
    Nomura, M
    Hishida, H
    CIRCULATION, 2005, 112 (17) : U404 - U405
  • [6] B-type natriuretic peptide in the emergency diagnosis of diastolic dysfunction heart failure
    Maisel, AS
    Hlavin, P
    McCord, J
    Nowak, RM
    Hollander, JE
    Duc, P
    Steg, G
    Omland, T
    Westheim, A
    Abraham, WT
    Storrow, AB
    McKay, CA
    Wu, AH
    McCullough, PA
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (05) : 140A - 140A
  • [7] B-type natriuretic peptide in heart failure
    Hassan, Y
    Shapira, AR
    Hassan, S
    NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (24): : 1976 - 1977
  • [8] B-type natriuretic peptide in heart failure
    Moe, Gordon W.
    CURRENT OPINION IN CARDIOLOGY, 2006, 21 (03) : 208 - 214
  • [9] Optimization of the use of B-type natriuretic peptide levels for risk stratification at discharge in elderly patients with decompensated heart failure
    Cournot, Maxime
    Mourre, Fabien
    Castel, Fabienirie
    Ferrieres, Jean
    Destrac, Sylvain
    AMERICAN HEART JOURNAL, 2008, 155 (06) : 986 - 991
  • [10] Management of diastolic heart failure in older adults - B-type natriuretic peptide was not mentioned
    Walsh, KM
    BRITISH MEDICAL JOURNAL, 2004, 328 (7452): : 1379 - 1379